Drug-resistant and immune-escape HBV mutants in HIV-infected hosts

Antiviral Therapy

Volumn 15, Issue 3 PART B, 2010, Pages 493-497

  Lacombe, Karine ^a,b,c   Boyd, Anders ^a   Gozlan, Joel ^c   Lavocat, Fabien ^a   Girard, Pierre Marie ^a,b,c   Zoulim, Fabien ^a,d  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; HEPATITIS B VACCINE;

ANTIVIRAL RESISTANCE; COMORBIDITY; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC ORIGIN; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSURVEILLANCE; INDUCED MUTATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MIXED INFECTION; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; STRUCTURAL GENE; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; ANIMAL; COMPLICATION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; MUTATION; VIROLOGY;

ANIMALS; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; MUTATION;

EID: 77953459314     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1495     Document Type: Review

References (40)

1. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the 'Mortalite 2000 and 2005' surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-598.
2. Thio CL, Seaberg EC, Skolasky R, Jr., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicentre Cohort Study (MACS). Lancet 2002; 360:1921-1926.
3. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009; 48:1763-1771.
4. Salmon-Ceron D, Rosenthal E, Lewden C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalite 2005 study. J Hepatol 2009; 50:736-745.
5. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686. (Pubitemid 43374518)
6. Lee W. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-1745.
7. Ganem D, Prince AM, Hepatitis B. Virus infection - natural history and clinical consequences. N Engl J Med 2004; 350:1118-1129. (Pubitemid 38298992)
8. Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus Res 2007; 127:164-176. (Pubitemid 47064411)
9. Olinger CM, Jutavijittum P, Hübschen JM, et al. Possible new hepatitis B virus genotype, Southeast Asia. Emerg Infect Dis 2008; 14:1777-1780.
10. Tatematsu K, Tanaka Y, Kurbanov F, et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol 2009; 83:10538-10547.
11. Lacombe K, Massari V, Girard PM, et al. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS 2006; 20:419-427.
12. Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20:863-870. (Pubitemid 43731568)
13. Ramos B, Nunez M, Martin-Carbonero l, et al. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr 2007; 44:557-561. (Pubitemid 46594899)
14. Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006; 44:1110-1116. (Pubitemid 44748362)
15. Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV/ HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008; 48:1062-1069.
16. Thomas HC. The hepatitis B virus and the host response. J Hepatol 1990; 11:S83-S89.
17. Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 1996; 98:2268-2276. (Pubitemid 26394200)
18. Parekh S, Zoulim F, Ahn SH, et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol 2003; 77:6601-6612. (Pubitemid 36666854)
19. Jammeh S, Tavner F, Watson R, Thomas HC, Karayiannis P. Effect of basal core promoter and pre-core mutations on hepatitis B virus replication. J Gen Virol 2008; 89:901-909.
20. Hasegawa K, Huang J, Rogers SA, Blum HE, Liang TJ. Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J Virol 1994; 68:1651-1659. (Pubitemid 24065731)
21. Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991; 324:1705-1709.
22. Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81:67-74. (Pubitemid 30047907)
23. Kato H, Orito E, Gish RG, et al. Characteristics of hepatitis B virus isolates of genotype G and their phylogenetic differences from the other six genotypes (A through F). J Virol 2002; 76:6131-6137. (Pubitemid 34556308)
24. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302-1306. (Pubitemid 29510871)
25. Pessoa MG, Gazzard B, Huang AK, et al. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 2008; 22:1779-1787.
26. Low E, Cox A, Atkins M, Nelson M. Telbivudine has activity against HIV-1. AIDS 2009; 23:546-547.
27. Avila C, Karwowska S, Lai C, Evans T. Telbivudine has no in vitro activity against laboratory and clinical HIV-1, including 5 clades and drug-resistant clinical isolates. 16th Conference on Retroviruses and Opportunisic Infections. 8-11 February 2009, Montréal, QC, Canada. Abstract 142.
28. Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006; 44:62-67. (Pubitemid 41772517)
29. Lacombe K, Ollivet A, Gozlan J, et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. AIDS 2006; 20:2229-2231. (Pubitemid 44684715)
30. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009; 49:1158-1165.
31. Audsley J, Arrifin N, Yuen LK, et al. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. HIV Med 2009; 10:229-235.
32. Lacombe K, Boyd A, Lavocat F, et al. Treament-induced and vaccine escape HBV mutants in HIV-HBV co-infected patients: a longitudinal analysis. Annual Meeting for the American Association for the Study of Liver Diseases. 30 October-3 November 2009, Boston, MA, USA. Abstract 218.
33. Fung S, Marzzuli T, Sherman M, Popovic V. Tenofovir (TDF) is effective in lamivudine (LAM)- resistant chronic hepatitis B patients who harbour rtA194T as baseline. Annual Meeting for the American Association for the Study of Liver Diseases. 30 October-3 November 2009, Boston, MA, USA. Abstract 399.
34. Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27:254-263.
35. Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a tertiary hospital. J Med Virol 2009; 81:406-412.
36. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336:325-329.
37. Tian Y, Xu Y, Zhang Z, et al. The amino acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen. J Clin Microbiol 2007; 45:2971-2978.
38. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002; 25:97-106.
39. Kamili S, Sozzi V, Thompson G, et al. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 2009; 49:1483-1491.
40. Svicher V, Forbici F, Alteri C, et al. HIV-driven immunosuppression regulates HBV evolution in HBV/ HIV-co-infected patients. 16th Conference on Retroviruses and Opportunisic Infections. 8-11 February 2009. Montréal, QC, Canada. Abstract 100.